{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:41:11Z","timestamp":1784432471935,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.011","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:02:59Z","timestamp":1719990179000},"page":"759-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improving Access to T-Cell Therapies in Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A","family":"Derman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.06.011_bib0001","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.06.011_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.06.011_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.06.011_bib0004","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.06.011_bib0005","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clml.2024.06.011_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2024.06.011_bib0007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2023.11846","article-title":"Fair allocation of scarce CAR T-cell therapies for relapsed\/refractory multiple myeloma","volume":"330","author":"Derman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2024.06.011_bib0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2024.06.011_bib0009","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.06.011_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.011_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.HS9.0000829648.85784.e2","article-title":"P19: Baseline correlates of complete response to idecabtagene vicleucel (IDE-CEL, BB2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the Karmma trial","volume":"6","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"Hemasphere"},{"issue":"14","key":"10.1016\/j.clml.2024.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.06.011_bib0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.06.011_bib0014","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.011_bib0015","first-page":"1514","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: U.S. myeloma immunotherapy consortium real world experience","volume":"109","author":"Hashmi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.06.011_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. myeloma immunotherapy consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.06.011_bib0017","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2023-181344","article-title":"Patients with private insurance endure significantly longer delays in time from intent to CAR-T to apheresis (brain-2-vein) in multiple treated diffuse large B-cell lymphoma: analysis by cellular therapy intent quotient (CTIQ)","volume":"142","author":"Gromowsky","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.011_bib0018","unstructured":"Miller M and Fields R (2023). Insurance Executives Refused to Pay for the Cancer Treatment That Could Have Saved Him. This Is How They Did It. https:\/\/www.propublica.org\/article\/priority-health-michigan-cart-insurance-vanpatten-denials. Accessed May 1, 2024."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:51Z","timestamp":1729595391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002453"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Access to T-Cell Therapies in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}